Hemophagocytic Lymphohistiocytosis Hlh

Disclaimer: This information is intended for educational purposes and as a clinical reference for healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made based on individual patient assessment, current best evidence, and the clinician's judgment. Always consult with a qualified healthcare provider for any health concerns or before making any decisions related to patient care.

Overview

• Definition: Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening syndrome of severe systemic inflammation and immune dysregulation characterized by uncontrolled activation and proliferation of histiocytes and T lymphocytes, leading to widespread tissue infiltration and cytokine storm. It is not a malignancy but can mimic one and often has an underlying trigger.
• Epidemiology:
  • Incidence: Estimated incidence of 1 in 50,000 to 1 in 800,000 live births for primary (familial) HLH, though the true incidence may be higher due to underdiagnosis. Acquired (secondary) HLH is more common, particularly in adults, often triggered by infections, malignancy, or autoimmune conditions.
  • Age: Primary HLH typically presents in infancy or early childhood, with a median age of onset around 1 year. Secondary HLH can occur at any age but is more prevalent in older children and adults.
  • Sex: No significant sex predisposition for primary HLH. Secondary HLH may show slight variations depending on the underlying trigger (e.g., more common in males for EBV-associated HLH).
• Classification: HLH is broadly classified into two main categories based on etiology:
  • Primary (Familial) HLH (FHL): Caused by inherited genetic defects affecting granule-dependent cytotoxicity pathways in NK cells and cytotoxic T lymphocytes (CTLs). Autosomal recessive inheritance is common. Subtypes are classified by the gene involved (e.g., FHL1-FHL5 and others, including Griscelli syndrome type 2, Chédiak-Higashi syndrome, X-linked lymphoproliferative disease (XLP-1 and XLP-2), and Hermansky-Pudlak syndrome type 2).
  • Secondary (Acquired) HLH: Occurs in individuals without an identified underlying genetic defect but is triggered by severe immune activation. Triggers include:
    • Infections: Epstein-Barr Virus (EBV) is the most common viral trigger, but CMV, HIV, parvovirus B19, bacterial, fungal, and parasitic infections can also incite HLH.
    • Malignancies: Lymphomas (especially T-cell and NK-cell lymphomas), leukemias, solid tumors. This is often termed malignancy-associated HLH (MAH-HLH).
    • Autoimmune/Autoinflammatory Diseases: Often referred to as Macrophage Activation Syndrome (MAS) when associated with rheumatologic conditions (e.g., systemic juvenile idiopathic arthritis (sJIA), SLE, adult-onset Still's disease).
    • Immunodeficiencies: Less common, but certain primary immunodeficiencies can predispose to HLH.
    • Drug-induced: Rare, but certain medications can trigger HLH.
    • Idiopathic: Cases where no underlying cause or genetic defect is identified.

Pathophysiology

• Mechanism: HLH is characterized by a pathological immune activation loop. Normally, NK cells and CTLs eliminate infected or malignant cells by releasing cytotoxic granules containing perforin and granzymes. In HLH, defective granule-dependent cytotoxicity (due to genetic defects in primary HLH or overwhelming activation in secondary HLH) leads to inefficient clearance of activated immune cells and infectious agents.
  • This results in persistent activation and proliferation of histiocytes (macrophages) and T lymphocytes, which continuously release pro-inflammatory cytokines (e.g., IFN-γ, TNF-α, IL-6, IL-1β).
  • The uncontrolled cytokine release (cytokine storm) causes widespread systemic inflammation, multi-organ damage, and the characteristic clinical features of HLH.
  • Hemophagocytosis (phagocytosis of blood cells by activated macrophages) is a hallmark but not universally present and can be seen in other conditions. It contributes to cytopenias.
• Risk Factors:
  • For Primary HLH: Family history of HLH, consanguinity, specific genetic mutations (e.g., PRF1, UNC13D, STX11, STXBP2, SH2D1A, BIRC4, ITK, RAB27A, LYST, AP3B1).
  • For Secondary HLH:
    • Severe infections (especially EBV, CMV).
    • Hematologic malignancies (lymphoma, leukemia).
    • Autoimmune/autoinflammatory diseases (sJIA, SLE).
    • Immunosuppression followed by infection (e.g., post-transplant).
    • Specific ethnic backgrounds for certain genetic predispositions.
• Protective Factors: There are no known specific protective factors against developing HLH, given its underlying genetic or severe immune activation basis. Early diagnosis and prompt, aggressive treatment are crucial for improving outcomes and mitigating damage.

Clinical Presentation

HLH presents as an acute, severe inflammatory syndrome. The symptoms are often non-specific, mimicking severe sepsis or other inflammatory conditions, making diagnosis challenging.

Signs and Symptoms

• Cardinal Features:
  • Prolonged Fever: Often persistent and unresponsive to antibiotics, typically >38.5°C.
  • Hepatosplenomegaly: Enlargement of the liver and/or spleen, especially the spleen. Splenomegaly is present in >90% of cases.
  • Cytopenias: Affecting at least two of three lineages: anemia, thrombocytopenia, neutropenia.
  • Neurological Symptoms: Common in primary HLH and severe secondary cases, including irritability, lethargy, seizures, ataxia, nuchal rigidity, cranial nerve palsies, altered mental status, and coma.
  • Rash: Maculopapular, petechial, or purpuric rash, often non-specific.
• Early Signs:
  • Persistent fever, often with a rapid decline in general condition.
  • Progressive cytopenias despite supportive care.
  • Increasing fatigue and irritability (especially in children).
  • Initial signs of hepatomegaly/splenomegaly.
• Advanced Signs:
  • Severe coagulopathy (DIC).
  • Multi-organ dysfunction (renal failure, hepatic failure, respiratory distress).
  • Severe neurological deterioration.
  • Significant hemorrhage due to severe thrombocytopenia and coagulopathy.
  • Anasarca/edema due to hypoalbuminemia (due to hepatic dysfunction and capillary leak).
• Atypical Presentations:
  • HLH can present with dominant features related to the underlying trigger (e.g., predominant neurological symptoms, isolated cytopenia, or only moderate fever).
  • Lack of classic diagnostic criteria initially, requiring close monitoring and repeat testing.
  • Some genetic forms (e.g., XLP) may present with fulminant mononucleosis.

Physical Examination

• Inspection:
  • General: Ill appearance, lethargy, irritability.
  • Skin: Maculopapular rash, petechiae, purpura, jaundice, pallor, generalized edema/anasarca.
  • Mucous membranes: Pallor, signs of bleeding (gingival bleeding, epistaxis).
• Palpation:
  • Abdomen: Splenomegaly (often firm and tender), hepatomegaly.
  • Lymph Nodes: Lymphadenopathy (generalized or localized).
• Special Tests:
  • Neurological Exam: Assess for signs of CNS involvement (nuchal rigidity, ataxia, altered mental status, focal neurological deficits, seizures).
  • Fundoscopy: May reveal retinal hemorrhages or papilledema in severe CNS involvement.

Diagnostic Approach

A high index of suspicion is critical for timely diagnosis, as HLH is a rapidly progressive and fatal disease if untreated. The HLH-2004 diagnostic criteria are widely used for diagnosis.

History Taking

• Key Questions:
  • Fever pattern: Onset, duration, magnitude, response to antipyretics/antibiotics.
  • Infection exposure: Recent viral illnesses (especially EBV, CMV), travel history, exposure to immunocompromised individuals.
  • Bleeding/Bruising: Easy bruising, petechiae, nosebleeds, gum bleeding, gastrointestinal bleeding.
  • Neurological changes: Irritability, lethargy, seizures, changes in gait or speech, headache, visual disturbances.
  • Gastrointestinal symptoms: Abdominal pain, vomiting, diarrhea, jaundice.
  • Family history: Any family members with similar recurrent fevers, immune problems, unexplained deaths, or a prior diagnosis of HLH. This is crucial for suspecting primary HLH.
  • Medication history: Recent new medications.
  • Underlying conditions: History of autoimmune diseases (sJIA, SLE), known immunodeficiencies, or malignancy.
• Red Flags:
  • Persistent high fever despite broad-spectrum antibiotics.
  • Rapidly worsening multi-lineage cytopenias.
  • Significant and progressive hepatosplenomegaly.
  • Sudden onset of neurological symptoms in the context of systemic illness.
  • Extremely high ferritin levels (often >10,000 µg/L).

Laboratory Tests

Diagnosis of HLH requires meeting at least 5 out of 8 of the diagnostic criteria defined by the Histiocyte Society HLH-2004 protocol, OR molecular diagnosis consistent with HLH.

• First-Line (Initial Screening & Diagnostic Criteria Tests):

  1. Fever: Peak temperature ≥38.5°C for >7 days.
  2. Splenomegaly: Palpable >3 cm below the costal margin.
  3. Cytopenias affecting ≥2 cell lines:
     • Hemoglobin <9 g/dL (age <4 weeks: <10 g/dL)
     • Platelets <100 x 10^9/L
     • Neutrophils <1.0 x 10^9/L
  4. Hypertriglyceridemia: Fasting triglycerides ≥3.0 mmol/L (≥265 mg/dL).
  5. Hypofibrinogenemia: Fibrinogen ≤1.5 g/L.
  6. Ferritin: Elevated, typically ≥500 µg/L. Critically, levels often reach >10,000 µg/L in florid HLH and are a strong indicator.
  7. Soluble CD25 (sIL-2Rα): Elevated, typically ≥2400 U/mL (or >2 standard deviations above age-adjusted normal). This is a marker of T-cell activation.
  8. Low or absent Natural Killer (NK) cell activity: Assessed by flow cytometry (e.g., CD107a degranulation assay) or functional cytotoxicity assay. Values <2.5% or significantly below normal range are indicative.

• Confirmatory (Specific & Etiology-Focused Tests):

  • Bone Marrow Aspiration and Biopsy: To identify hemophagocytosis (activated benign macrophages phagocytosing erythrocytes, leukocytes, platelets, or their precursors). While often present, it's not required for diagnosis and its absence does not rule out HLH. Its presence in other tissues (spleen, lymph nodes, liver, CSF) also counts.
  • Genetic Testing: For primary HLH, sequencing of known causal genes (e.g., PRF1, UNC13D, STX11, STXBP2, RAB27A, LYST, AP3B1, SH2D1A, BIRC4, etc.). This can confirm primary HLH even if not all 5/8 criteria are met.
  • Viral Serologies/PCR: EBV (viral load, specific antibody titers), CMV, HSV, VZV, Adenovirus, Parvovirus B19, HIV, etc., to identify infectious triggers. EBV viral load (DNA copies/mL) is particularly important.
  • Immunological Studies:
    • Lymphocyte subset analysis (flow cytometry) to assess T, B, NK cell numbers.
    • Perforin expression on NK/T cells (flow cytometry).
    • Granzyme B levels.
  • Coagulation Profile: PT, aPTT, D-dimer, fibrinogen, ATIII to assess for disseminated intravascular coagulation (DIC).
  • Liver Function Tests: Bilirubin, AST, ALT, LDH (often significantly elevated).
  • Renal Function Tests: Creatinine, BUN.
  • Cerebrospinal Fluid (CSF) Analysis: If neurological symptoms present: cell count, protein, glucose, EBV PCR, sCD25, cytology (for hemophagocytosis or malignant cells).

• Monitoring:

  • Daily/Frequent: Complete Blood Count (CBC) with differential, Ferritin, LFTs, Coagulation profile, Triglycerides.
  • Weekly/Bi-weekly: sCD25, inflammatory markers (CRP, ESR).
  • As needed: Repeat viral loads, genetic testing if initial results are inconclusive, bone marrow biopsy for response assessment or if new cytopenias arise.

Imaging

• Recommended:
  • Abdominal Ultrasound/CT: To confirm and quantify hepatosplenomegaly, assess for lymphadenopathy, and exclude other causes of abdominal symptoms.
  • Chest X-ray/CT: To assess for pulmonary infiltrates (pneumonitis) or effusions, which can be seen in HLH or associated infections/malignancy.
  • Brain MRI with Gadolinium: Recommended for all patients with neurological symptoms, and often considered even in asymptomatic patients with primary HLH given the high incidence of CNS involvement. May show white matter lesions, periventricular abnormalities, leptomeningeal enhancement, or diffuse cerebral edema.
• Advanced:
  • PET-CT: May be used to rule out underlying malignancy, especially lymphoma, when clinical suspicion remains high.
  • Echocardiogram: To assess for cardiac dysfunction, especially if there are signs of heart failure.

Management

Management of HLH is complex and requires a multidisciplinary team approach. It involves both immediate immunosuppression to control the hyperinflammation and targeted therapy for the underlying cause (if identifiable).

Acute Management

• Immediate (First-hour interventions):
  • Stabilize patient: ABCs (Airway, Breathing, Circulation). Correct hypoxemia, manage shock with fluid resuscitation and vasopressors if necessary.
  • Initiate broad-spectrum antibiotics: Empiric antibiotics are often started immediately given the high risk of infection and similarity to sepsis. Antifungals and antivirals (e.g., acyclovir for HSV, ganciclovir for CMV) may be added based on suspicion.
  • Blood product support: Transfuse packed red blood cells for anemia, platelets for thrombocytopenia (<20-50 x 10^9/L or active bleeding), fresh frozen plasma/cryoprecipitate for coagulopathy.
  • Consider ICU admission: For patients with severe multi-organ dysfunction or rapid deterioration.
• Stabilization (Early management priorities):
  • Diagnosis confirmation: Expedite diagnostic workup for HLH and underlying etiology.
  • Initiate immunosuppressive therapy: Once HLH is strongly suspected and infectious causes are reasonably excluded or treated, therapy should be initiated without delay. The HLH-2004 protocol is the standard first-line regimen.
    • Dexamethasone: Potent corticosteroid, usually 10 mg/m²/day IV, divided into 2 doses, for 2 weeks, then tapered according to protocol. Dexamethasone crosses the blood-brain barrier, making it effective for CNS involvement.
    • Etoposide (VP-16): Cytotoxic agent that induces apoptosis in activated lymphocytes and histiocytes. Initial dose is typically 150 mg/m² IV, twice weekly for 8 weeks (total 16 doses). Subsequent doses are adjusted based on count recovery and disease response.
    • Intrathecal Methotrexate/Hydrocortisone: For patients with confirmed or suspected CNS involvement (symptoms, abnormal CSF/MRI). Often administered weekly for the first 8 weeks.
    • Cyclosporine A (CsA): Calcineurin inhibitor, inhibits T-cell activation. Typically started after 2 weeks of dexamethasone/etoposide. Oral dose adjusted to achieve target trough levels (e.g., 200-400 ng/mL).
• Emergency (Crisis management):
  • Management of DIC: Aggressive blood product support, consider tranexamic acid for bleeding, address underlying HLH.
  • Severe hyperinflammation: Consider urgent measures like plasmapheresis in highly refractory or severe cases, though evidence is limited.
  • Airway management: Intubation and mechanical ventilation for respiratory failure.
  • Dialysis: For acute kidney injury.

Chronic Management

• Pharmacological:
  • Continuation of HLH-2004 protocol: Following the initial 8-week induction, treatment continues with pulsing etoposide, cyclosporine, and corticosteroids, often for a total of 40 weeks, followed by maintenance therapy.
  • Targeted therapies for specific triggers:
    • EBV-associated HLH: Rituximab (anti-CD20) may be added if B cells are involved, particularly in severe or refractory cases.
    • MAS/sJIA-associated HLH: High-dose corticosteroids, anakinra (IL-1 receptor antagonist), tocilizumab (IL-6 receptor antagonist), or ruxolitinib (JAK1/2 inhibitor) may be used first-line or as salvage, as these agents target specific cytokines involved in MAS pathogenesis.
    • Malignancy-associated HLH: Treatment of the underlying malignancy is paramount. HLH-directed therapy may be used concurrently.
• Non-pharmacological:
  • Hematopoietic Stem Cell Transplantation (HSCT): The only curative option for primary HLH and certain refractory secondary forms (e.g., relapsed EBV-HLH). Indications for HSCT include confirmed genetic diagnosis of FHL, refractory HLH, or recurrent HLH.
  • Supportive care: Nutritional support, infection prophylaxis (PCP, fungal), psychological support for patients and families.
• Monitoring:
  • Regular clinical assessment: Fever, hepatosplenomegaly, neurological status.
  • Laboratory monitoring: Weekly/bi-weekly CBC, ferritin, LFTs, triglycerides, sCD25, viral loads (if applicable), cyclosporine levels.
  • Imaging: Repeat brain MRI for CNS involvement.
  • Genetic counseling: For families with primary HLH.

Treatment Algorithms

• First-Line:
  • HLH-2004 Protocol: For newly diagnosed HLH meeting criteria.
    • Week 1-2: Dexamethasone 10 mg/m²/day IV + Etoposide 150 mg/m² IV twice weekly.
    • Week 3-8: Dexamethasone tapered (e.g., 5 mg/m²/day for 2 weeks, then 2.5 mg/m²/day for 2 weeks, then 1.25 mg/m²/day for 2 weeks) + Etoposide 150 mg/m² IV weekly. Cyclosporine A oral started after week 2, titrated to levels. Intrathecal therapy (methotrexate 12 mg + hydrocortisone 15 mg) weekly for CNS involvement.
    • Maintenance (after week 8): Etoposide every 3-4 weeks + Cyclosporine A + Dexamethasone pulses (e.g., 10 mg/m²/day for 3 days every 2 weeks). Total duration usually 40 weeks, or until HSCT.
• Second-Line (Refractory/Relapsed/Alternative):
  • Alemtuzumab (anti-CD52): For refractory disease, particularly in children awaiting HSCT or with high risk of relapse. Doses typically 1-1.5 mg/kg IV thrice weekly for a few weeks.
  • Ruxolitinib (JAK1/2 inhibitor): Increasingly used, especially in adult HLH and MAS, or as salvage therapy. Oral dosing depends on weight (e.g., 5-15 mg twice daily). Effective by blocking IFN-gamma signaling.
  • Anakinra (IL-1 receptor antagonist): Primarily for MAS, but increasingly used in severe secondary HLH without strong evidence of primary HLH. Doses up to 10 mg/kg/day IV or SC.
  • Emapalumab (anti-IFN-gamma antibody): FDA-approved for primary HLH refractory to conventional therapy. Blocks interferon-gamma, a key cytokine in HLH pathogenesis. Doses are weight-based.
  • Daclizumab (anti-CD25): Investigational, targets IL-2 receptor.
  • IVIG: Can be considered in severe infections or to modulate immune response, but not a primary HLH treatment.
• Refractory Cases:
  • Escalation of existing therapy.
  • Switch to alternative agents (e.g., from HLH-2004 to ruxolitinib, emapalumab, or alemtuzumab).
  • Urgent consideration for HSCT if a suitable donor is available, especially for primary HLH.
  • Combination of multiple agents.

Complications

• Common:
  • Infections: Due to immunosuppression and underlying immune dysregulation.
  • Coagulopathy/Bleeding: Due to thrombocytopenia, hypofibrinogenemia, DIC.
  • Anemia: Requires frequent transfusions.
  • Hepatomegaly/Splenomegaly: Can lead to pain, pressure symptoms.
• Serious:
  • Multi-organ Failure: Liver failure, renal failure, respiratory failure (ARDS).
  • Central Nervous System (CNS) Damage: Seizures, stroke, permanent neurological deficits, cognitive impairment, hydrocephalus.
  • Severe Hemorrhage: Intracranial hemorrhage is a major cause of mortality.
  • Opportunistic Infections: Due to severe immunosuppression from treatment.
• Long-term:
  • Neurological Sequelae: Learning disabilities, developmental delay, motor deficits.
  • Endocrine Issues: Growth hormone deficiency, hypothyroidism, hypogonadism (from etoposide/HSCT).
  • Infertility: Especially after HSCT.
  • Secondary Malignancies: Increased risk after HSCT or due to etoposide.
  • Chronic infections: Persistent viral carriage (e.g., EBV).

Prognosis

Prognosis has significantly improved with earlier diagnosis and adherence to treatment protocols like HLH-2004, but it remains a life-threatening condition.

• Factors Affecting Outcome:
  • Underlying etiology: Primary HLH generally has a poorer prognosis without HSCT. Secondary HLH prognosis often depends on the treatability of the underlying trigger (e.g., resolving infection vs. refractory malignancy).
  • Timeliness of diagnosis and treatment: Delay in initiation of specific therapy is associated with worse outcomes.
  • Presence of CNS involvement: Predicts worse prognosis and higher risk of long-term neurological deficits.
  • Response to initial therapy: Non-responders or those with relapsed disease have worse outcomes.
  • Genetic subtype: Some genetic mutations (e.g., PRF1) are associated with more severe disease.
  • Age at onset: Very young children (infants) with primary HLH may have a more aggressive course.
• Survival:
  • Historically, HLH was almost universally fatal.
  • With HLH-2004 protocol, survival rates for primary HLH undergoing HSCT are around 60-70%.
  • For secondary HLH, survival rates are variable, ranging from 50% to over 80%, largely depending on the underlying trigger and its response to therapy. Early recognition of MAS in rheumatologic conditions has improved outcomes dramatically.
• Quality of Life: Survivors, especially those with CNS involvement, may experience significant long-term neurological and cognitive impairments. Close follow-up and rehabilitation are essential.

Prevention

HLH, particularly primary HLH, is not preventable. However, secondary HLH can sometimes be prevented or mitigated by addressing the underlying trigger.

• Primary: Not applicable due to genetic or severe immune activation nature.
• Secondary:
  • Early detection of genetic predisposition: Genetic counseling and preimplantation genetic diagnosis for families with known primary HLH mutations.
  • Vigilance for triggers: Prompt and effective treatment of severe infections (especially EBV), early diagnosis and treatment of underlying malignancies or autoimmune diseases that can trigger HLH.
  • Awareness in high-risk groups: Clinicians caring for patients with systemic JIA or other severe autoimmune diseases should be highly vigilant for signs of MAS/HLH.
• Tertiary: Preventing complications involves timely and aggressive treatment of HLH itself, management of side effects of therapy, and proactive screening for long-term sequelae (e.g., neurological, endocrine).

Special Populations

• Pediatric:
  • Primary HLH: More common in this age group, often presenting in infancy. Genetic testing is critical. HSCT is the definitive cure. Long-term neurological complications are a major concern.
  • MAS: Systemic JIA is a common trigger for secondary HLH/MAS in children.
• Geriatric:
  • Secondary HLH is more common, often associated with malignancy (lymphoma) or infections.
  • Diagnosis can be challenging due to non-specific symptoms and comorbidities.
  • Treatment regimens may need dose adjustments due to organ dysfunction and increased risk of toxicities.
• Pregnancy:
  • Very rare but extremely serious. Diagnosis is challenging due to overlapping symptoms with preeclampsia or HELLP syndrome.
  • Treatment decisions must balance maternal and fetal well-being. Corticosteroids can be used. Etoposide is generally avoided if possible but may be necessary for life-saving treatment. Deliver if stable and near term.
• Comorbidities:
  • Immunodeficiencies: Patients with known or suspected immunodeficiencies are at higher risk of HLH. Management requires careful consideration of the underlying immune defect.
  • Malignancy: Treatment of malignancy-associated HLH requires coordinated care with oncology. Chemotherapy for the malignancy is often initiated concurrently with HLH-directed therapy.
  • Autoimmune Disease: For MAS/HLH, the focus is often on high-dose corticosteroids, anakinra, or ruxolitinib. Close collaboration with rheumatology is essential.

Clinical Pearls

• Diagnostic:
  • Ferritin is your friend: While >500 µg/L is a criterion, ferritin levels >10,000 µg/L are highly suggestive of HLH and should trigger immediate investigation. However, even high ferritin is not specific and can be seen in sepsis, liver failure, etc.
  • High index of suspicion: HLH mimics many conditions (sepsis, severe infection, malignancy, autoimmune flare). Think of HLH in any patient with unexplained persistent fever, cytopenias, and hepatosplenomegaly.
  • Don't wait for all criteria: If HLH is highly suspected and the patient is deteriorating, initiate treatment based on clinical judgment, even if all 5/8 criteria are not yet met or results are pending (e.g., NK cell activity or sCD25).
  • Bone marrow hemophagocytosis: Its absence does NOT rule out HLH, as it can be patchy. Its presence is supportive but not diagnostic on its own.
  • Look for the trigger: Always actively search for an underlying infection, malignancy, or autoimmune disease. This guides specific management and prognostic outlook.
• Treatment:
  • Early and aggressive: Prompt initiation of immunosuppressive therapy is key to survival. Delays are detrimental.
  • Consider CNS involvement: High prevalence in primary HLH; evaluate with MRI and CSF, and treat intrathecally if indicated.
  • Supportive care is vital: Blood product support, infection prophylaxis, and management of multi-organ failure.
  • HSCT for cure: Emphasize HSCT for primary HLH and appropriate secondary HLH cases.
• Pitfalls:
  • Misdiagnosis: As sepsis, liver failure, pure hematologic malignancy, or severe autoimmune flare, leading to delayed appropriate treatment.
  • Over-reliance on single test: No single test confirms or excludes HLH; it's a constellation of clinical and laboratory findings.
  • Treating only the trigger: Failure to recognize and treat the hyperinflammatory syndrome of HLH itself.
  • Stopping therapy too soon: HLH requires prolonged treatment to prevent relapse and allow for definitive therapy (e.g., HSCT).

Recent Updates

• Guidelines:
  • The HLH-2004 protocol remains the standard of care for initial therapy. Newer international guidelines continue to refine diagnostic algorithms and treatment strategies.
  • Recommendations for management of MAS in rheumatologic conditions (e.g., by EULAR/ACR) increasingly incorporate biologics like anakinra or tocilizumab as initial therapies before or in conjunction with corticosteroids.
• Evidence:
  • Emapalumab (anti-IFN-gamma): FDA approval in 2018 for primary HLH refractory to conventional therapy or relapsed/refractory disease. Clinical trials demonstrated high response rates in these difficult-to-treat patients.
  • Ruxolitinib (JAK1/2 inhibitor): Growing evidence for its efficacy in both adult and pediatric HLH, especially in refractory or relapsed settings, and in MAS. It acts upstream of IFN-gamma signaling. Clinical trials are ongoing to assess its role earlier in therapy.
  • Immunosuppression and HSCT: Ongoing research focuses on optimizing conditioning regimens for HSCT to reduce toxicity while maintaining efficacy, and identifying patients who may not need HSCT.
  • Genetics: Discovery of new genetic defects associated with primary HLH continues, expanding the understanding of disease mechanisms and enabling more precise diagnosis.
• Controversies:
  • Role of genetic testing: While critical for primary HLH, when to perform it in adults presenting with secondary HLH remains debated (e.g., all adults vs. only those with recurrent disease or suspicious family history).
  • Optimal initial therapy for secondary HLH: Whether to use HLH-2004, or to start with more targeted therapies (e.g., anakinra, ruxolitinib) if an autoimmune trigger is suspected, is an area of active research.
  • Biomarkers: Continued search for more specific and sensitive biomarkers for early diagnosis and monitoring of response, especially for differentiating HLH from sepsis or other inflammatory conditions.

Key References

• Guidelines:
  • Jordan, M. B., et al. (2014). "How I treat hemophagocytic lymphohistiocytosis." Blood, 124(7), 1034-1044. (Excellent clinical review based on HLH-2004)
  • Henter, J. I., et al. (2007). "HLH-2004: A revised protocol for the diagnosis and treatment of hemophagocytic lymphohistiocytosis." Pediatric Blood & Cancer, 48(2), 124-131. (The cornerstone protocol)
  • Schulert, G. S., & Cron, R. Q. (2020). "Diagnosis and Management of Macrophage Activation Syndrome." Pediatric Clinics of North America, 67(4), 699-715. (Focus on MAS)
• Studies:
  • Jordan, M. B., et al. (2020). "Emapalumab in Patients With Primary Hemophagocytic Lymphohistiocytosis." New England Journal of Medicine, 383(9), 813-825. (Landmark study for emapalumab)
  • La Rosée, P., et al. (2017). "Activity of ruxolitinib in adult patients with secondary hemophagocytic lymphohistiocytosis." Blood, 129(12), 1648-1652. (Early evidence for ruxolitinib in adult HLH)
• Reviews:
  • Palazzi, C., & Henter, J. I. (2021). "Hemophagocytic lymphohistiocytosis: current trends in pathogenesis and treatment." Blood, 138(2), 97-106.
  • Grifoni, A., et al. (2021). "Diagnosis and treatment of HLH in adults." Blood, 137(19), 2691-2703.

---